No Data
No Data
LifeSci Capital Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $70
Vera Therapeutics: Promising Growth Potential With Atacicept's Positive Data and Strategic Positioning
Vera Therapeutics Initiated With an Outperform at Scotiabank
Vera Therapeutics (NASDAQ:VERA) Has Debt But No Earnings; Should You Worry?
TD Cowen Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $60
Vera Therapeutics (VERA) Gets a Buy From TD Cowen